A limitation of this study is that the findings are restricted to two NSCLC cell lines and rely on in vitro assays; thus, further validation in additional models and in vivo systems will be necessary to confirm the broader relevance of the PKA–HA–p53 axis in nicotine-driven NSCLC progression. Here, TP53 is linked to non-small cell lung carcinoma.